Progress of Clinical Research on Trop2 in Solid Tumors
10.3971/j.issn.1000-8578.2025.24.0542
- VernacularTitle:Trop2在实体肿瘤中的临床研究进展
- Author:
Ying ZHANG
1
;
Yueping LIU
1
Author Information
1. Department of Pathology, The Fourth Hospital of Hebei Medical University/Hebei Cancer Hospital, Shijiazhuang 050011, China.
- Publication Type:REVIEWS
- Keywords:
Trop2;
Cancer;
Mechanism;
Structure;
Targeted therapy
- From:
Cancer Research on Prevention and Treatment
2025;52(1):79-86
- CountryChina
- Language:Chinese
-
Abstract:
Trophoblast cell surface antigen 2 (Trop2) is a glycoprotein that is barely expressed in normal tissues but highly expressed in malignant tumors; it is remarkably associated with poor prognosis. Various targeted therapeutics against Trop2, such as anti-Trop2 antibodies and antibody-drug conjugate drugs targeting Trop2, have been developed, and some therapeutics have been approved or are in clinical trials for cancer treatment. In this review, we comprehensively discuss the gene structure, mechanism of action, clinical research, drug development, and other aspects of Trop2 to provide references for the clinical development of effective and safe Trop2-targeting drugs.
